Ocugen – Consensus Indicates Potential 210.3% Upside

Broker Ratings

Ocugen with ticker code (OCGN) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 1 and 0.7 with the average target price sitting at 0.9. Now with the previous closing price of 0.29 this would imply there is a potential upside of 210.3%. The 50 day MA is 0.31 and the 200 day moving average is 0.34. The market capitalisation for the company is $130m. Company Website: http://www.ocugen.com

Ocugen, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company’s pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:

    Twitter
    LinkedIn
    Facebook
    Email
    Reddit

      AIM All Share Index